Alveolar Soft Part Sarcoma, from the CureRays guide library.

Alveolar soft part sarcoma is a rare, slow-growing soft-tissue cancer of young people that often forms a painless deep mass but has a strong tendency to spread quietly to the lungs and brain; because it resists ordinary chemotherapy, treatment relies on complete surgery, radiation to control the tumor where it started, and newer targeted and immune therapies for disease that has spread.

What it is.

Alveolar soft part sarcoma (ASPS) is a rare type of soft-tissue sarcoma — a cancer that begins in the body's connective tissues rather than in an organ lining. It most often affects teenagers and young adults, and in younger patients it tends to appear in the muscles of an arm or leg, while in adults it is also found in the trunk. Under the microscope its cells cluster into little nests that look like the air sacs (alveoli) of the lung, which is where its name comes from. ASPS is driven by a specific genetic change — a fusion of two genes called ASPSCR1 and TFE3 — that switches on signals telling the tumor to build new blood vessels. That rich blood supply helps explain two of its defining features: it grows slowly, often as a painless mass that a person may notice for months or even years before diagnosis, yet it readily releases cells into the bloodstream that travel to distant organs, especially the lungs and the brain. Because it can spread early and silently, many patients already have small deposits in the lungs when the original tumor is found. Unlike many sarcomas, ASPS does not respond well to traditional chemotherapy, so management depends on removing the original tumor completely, using radiation to control microscopic disease and reduce the chance of it returning where it started, and — for disease that has spread — newer medicines that block blood-vessel growth or harness the immune system, which have changed the outlook for this cancer in recent years.

How radiation treats it.

Radiation therapy treats alveolar soft part sarcoma by delivering precisely aimed beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. It plays two distinct roles in this disease. The first is local control of the original tumor. Like other soft-tissue sarcomas, ASPS doesn't stay neatly inside the visible mass — it pushes microscopic fingers of tumor into the surrounding muscle and connective tissue. If only the obvious tumor were removed, those microscopic extensions could be left behind and regrow. Radiation treats a wider zone around the tumor, sterilizing that microscopic disease so the operation can be smaller and more likely to preserve the limb, and so the cancer is far less likely to return at the original site. It can be given before surgery, using a smaller area and lower dose and sometimes shrinking the tumor to make removal easier, or after surgery to the tumor bed at a higher dose when needed. The second role is treating the distant deposits ASPS is prone to form. Because this cancer tends to grow slowly, a limited number of spots in the lungs or brain can often be controlled for a long time with focused, high-dose radiation rather than ongoing drug therapy alone. Stereotactic radiosurgery delivers a concentrated dose to a brain metastasis in one or a few sessions while sparing the surrounding brain, and stereotactic body radiation does the same for lung deposits. This matters especially for ASPS because traditional chemotherapy is largely ineffective against it, so radiation — alongside surgery, antiangiogenic pills, and immunotherapy — is one of the most reliable tools for keeping the disease in check at specific sites.

The ways we can treat it.

Preoperative (neoadjuvant) radiation. Radiation before surgery treats the rim of microscopic disease using a smaller field and lower dose, and can make a complete, limb-preserving removal more achievable.

Postoperative (adjuvant) radiation. Radiation to the tumor bed after surgery sterilizes any microscopic disease left behind, lowering the chance of the cancer returning at the original site, especially when margins are close.

Stereotactic radiosurgery (SRS) for brain metastases. Highly focused, high-dose radiation delivered in one or a few sessions can control brain deposits precisely while sparing surrounding healthy brain — important because ASPS has a particular tendency to reach the brain.

Stereotactic body radiation (SBRT) for lung metastases. Focused, high-dose beams can ablate a limited number of lung deposits without surgery, providing durable control of the slow-growing spots ASPS typically forms.

Questions we hear often.

Why is alveolar soft part sarcoma watched so carefully for spread when it grows slowly? Because slow growth and a tendency to spread are not opposites in this cancer — they happen together. ASPS often grows quietly at its original site for months or years, but it also releases cells into the bloodstream early, and those cells settle most often in the lungs and sometimes the brain, where they too may grow slowly. As a result, many people already have small distant deposits when the original tumor is found, even with no symptoms. That is why doctors scan the lungs and often image the brain at diagnosis and during follow-up — finding deposits while they are few and small makes it possible to remove them or treat them with focused radiation and achieve long-term control.

If chemotherapy doesn't work well, what treats ASPS? ASPS is one of the sarcomas that responds poorly to traditional chemotherapy, so treatment relies on other tools. For disease confined to one site, surgery to remove the tumor completely — usually combined with radiation to control microscopic disease — is the foundation. For disease that has spread, two newer approaches have changed the outlook: targeted pills that block the tumor's ability to build new blood vessels, and immunotherapy that activates the immune system against the cancer, which is unusually effective in ASPS. Focused high-dose radiation and surgery are also used to control a limited number of distant spots.

Can radiation treat ASPS that has spread to the brain or lungs? Yes. Because ASPS tends to grow slowly, a limited number of deposits can often be controlled for a long time with focused, high-dose radiation rather than surgery. For the brain, stereotactic radiosurgery delivers a concentrated dose to a deposit in one or a few sessions while sparing the surrounding brain. For the lungs, stereotactic body radiation can ablate a small number of spots without an operation. These targeted treatments are frequently combined with antiangiogenic or immune therapy, and for some people they provide years of control.

This guide is informational only. It is not medical advice — please confirm anything here with your care team.